Study Evaluating the Efficacy of an Ibuprofen Effervescent Tablet in the Treatment of Post-Surgical Dental Pain

NCT00631111

Last updated date
Study Location
Austin, Texas, 78705, United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Pain
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
16-40 years

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

PainAn Open-Label Study Of Celecoxib In Patients With Posttraumatic Pain
NCT00976716
  1. Funabashi, Chiba
  2. Ichikawa, Chiba
  3. Matsudo, Chiba
  4. Sagamihara, Kanagawa
  5. Ageo, Saitama
  6. Saitama-shi, Saitama
  7. Edogawaku, Tokyo
  8. Kotoku, Tokyo
  9. Nerimaku, Tokyo
  10. Toshimaku, Tokyo
  11. Kofu, Yamanashi
ALL GENDERS
20 Years+
years
MULTIPLE SITES
PainA Study of the Recovery Benefits After Treatment With Parecoxib/Valdecoxib in Patients Undergoing Abdominal Surgery
NCT00651300
  1. Port Macquarie, New South Wales
  2. Randwick, New South Wales
  3. Westmead, New South Wales
  4. Coopers Plain, Queensland
  5. Townsville, Queensland
  6. Heidelberg, Victoria
  7. Prahran, Victoria
  8. Perth, Western Australia
ALL GENDERS
18 Years+
years
MULTIPLE SITES
PainPlacebo Controlled Dose-Response Study Of PD-217,014 In The Treatment Of Postherpetic Neuralgia
NCT00159640
  1. Warrawong, New South Wales
  2. Westmead, New South Wales
  3. Kippa Ring, Queensland
  4. Maroochydore, Queensland
  5. Bedford Park, South Australia
  6. Perth, Western Australia
  7. Woodville,
  8. Kelowna, British Columbia
  9. Halifax, Nova Scotia
  10. Toronto, Ontario
  11. Sherbrooke, Quebec
  12. Ste-foy, Quebec
  13. Brno,
  14. Ceske Budejovice,
  15. CZ-Praha 8,
  16. Plzen,
  17. Praha 5,
  18. Arnhem,
  19. Breda,
  20. Kampen,
  21. Roosendaal,
  22. Rotterdam,
  23. Stadskanaal,
  24. Barcelona,
  25. Granada,
  26. Madrid,
  27. Malaga,
  28. Sevilla,
  29. Portsmouth, Hants
  30. Northampton, Northants
  31. London,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Study Evaluating the Efficacy of an Ibuprofen Effervescent Tablet in the Treatment of Post-Surgical Dental Pain
Official Title  ICMJE Ibuprofen 400 mg Effervescent Tablet Dental Pain Study II
Brief Summary Evaluation of the efficacy and safety of a single dose of an ibuprofen effervescent tablet in the treatment of pain following third molar extraction in comparison to single doses of placebo, standard ibuprofen tablets, and effervescent aspirin plus vitamin C tablets.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Condition  ICMJE Pain
Intervention  ICMJE
  • Drug: effervescent ibuprofen tablets
  • Drug: effervescent Aspirin plus Vitamin C tablets
  • Drug: ibuprofen tablets
  • Drug: placebo
Study Arms  ICMJE
  • Experimental: 1
    Intervention: Drug: effervescent ibuprofen tablets
  • Active Comparator: 2
    Intervention: Drug: effervescent Aspirin plus Vitamin C tablets
  • Active Comparator: 3
    Intervention: Drug: ibuprofen tablets
  • Placebo Comparator: 4
    Intervention: Drug: placebo
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: February 28, 2008)
270
Original Estimated Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE April 2008
Actual Primary Completion Date April 2008   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion:

  • Moderate or severe post-operative pain following surgical extraction of two or more third molars, at least one of which must be a partial or complete bony mandibular impaction
  • In general good health with no contraindications to the study medication or rescue medication (tramadol or acetaminophen + hydrocodone)
  • Use of only short-acting local anesthetics with or without vasocontrictor and/or nitrous oxide

Exclusion:

  • Presence of a serious medical condition (e.g., poorly controlled hypertension, diabetes, or hyper-/hypo-thyroidism; significantly impaired renal, cardiac, or hepatic function)
  • Acute localized dental alveolar infection at the time of surgery that could confound the post-surgical evaluation
  • Females who are pregnant, lactating, of child-bearing potential, or post-menopausal for less than 2 years and not using a medically-approved method of contraception
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 16 Years to 40 Years   (Child, Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00631111
Other Study ID Numbers  ICMJE AI-07-02
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Wyeth (Registry Contact: Clinical Trial Registry Specialist), Wyeth
Study Sponsor  ICMJE Wyeth is now a wholly owned subsidiary of Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Medical MonitorWyeth is now a wholly owned subsidiary of Pfizer
PRS Account Wyeth is now a wholly owned subsidiary of Pfizer
Verification Date July 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP